Peptide Library

Human study PLS-00205

Intraocular expression of thymosin β4 in proliferative diabetic retinopathy.

Cross-sectional study · Not reported participants enrolled · not included in the assessments (wrong compound)

Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Only the abstract was available. Essential methods may be missing, which limits what can be judged.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

  • Intraocular expression of thymosin β4 in proliferative diabetic retinopathy.primary · Acta ophthalmologica · 2011-02-18 · PMID 21332672 · DOI

Design and participants

Design
Cross-sectional study
Population
Patients with proliferative diabetic retinopathy (62) and patients with non-diabetic pre-retinal membranes (24), all undergoing pars plana vitrectomy.
Conditions
Proliferative diabetic retinopathy, Retinal neovascularization
Setting
Vitreoretinal surgery (pars plana vitrectomy); setting details not stated
Planned enrollment (registry)
Not reported
Enrolled
Not reported
Randomized
Not reported
Completed follow-up
Not reported
Funding
not stated
Authors’ conflicts
not stated

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

    What the authors reported

    As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

    Adverse events

    None reported. That is not evidence of safety.

    Monitoring: Not applicable; no compound was administered.

    The authors concluded (paraphrased): Thymosin β4 is produced in intraocular fibrovascular membranes of patients with proliferative diabetic retinopathy and in diabetic rats, and may play a role in diabetic retinal neovascularization.

    Peptide Library’s assessment

    An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

    Limitations

    • other: Endogenous thymosin β4 was only measured as a biomarker. It was never administered, so the study gives no evidence on treatment effects.
    • abstract only: Only the PubMed abstract is available, and part of the results sentence on mRNA levels is truncated.
    • inappropriate endpoint: Outcomes are tissue and fluid levels and expression markers (surrogate laboratory measures), not clinical outcomes.

    No risk-of-bias assessment has been published for this study’s results.

    Claims this study informs

    Where each value comes from

    • author_conclusion: PMID 21332672, abstract (Conclusions) · extracted by AI (automated, not verified by a person) · abstract only
    • design: PMID 21332672, abstract (Methods, sentences 1-3) · extracted by AI (automated, not verified by a person) · abstract only
    • participants: PMID 21332672, abstract (Methods, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
    • population: PMID 21332672, abstract (Methods, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only

    • Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

    These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).